225Ac-EBTATE

N/A

Report date: 2025/11/18 13:23:02

NME

Base Information

Drug Name225Ac-EBTATE

Drug Alias Name225-Actinium-EBTATEActinium 225 EBTATE225Ac-EBTATE

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionSomatostatin receptor 2 modulatorsIonising radiation emitters

TargetsSomatostatin receptor 2

Therapy Area/IndicationsSmall Cell Lung CarcinomaCarcinoma, Neuroendocrine

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMolecular Targeting Technologies Inc

China Registration ClassN/A

Develop Information

Active CompaniesMolecular Targeting Technologies Inc

Inactive CompaniesN/A

Active IndicationsSmall Cell Lung CarcinomaCarcinoma, Neuroendocrine

Inactive IndicationsN/A

Other Information

ATC CodeN/A